Self Reflected by Greg Dunn

We believe that the combination of psychedelic compounds, psychological support and digital companions will deliver a holistic and differentiated solution for difficult-to-treat medical conditions.


There is a global epidemic of psychiatric and neurological conditions with severe unmet needs and an opportunity for new and more effective treatments.1

1 in 4

People suffering from neurological and psychiatric disorders 2


Anticipated cost of treating global mental illness by 2030 3


Patients that do not respond to available treatments 4

1. Demyttenaere et al. WHO World Mental Health Survey Consortium (2004) · Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA, 291(21), 2581–2590.2. The World Health Report 2001: Mental Disorders affect one in four people3. The Lancet Global Health · Mental health matters4. Molecular Psychiatry · Treatment resistance in psychiatry: state of the art and new directions

Beckley Psytech is exploring how psychedelics can transform the treatment of neuropsychiatric conditions through its pipeline of investigational medicines.

By tailoring the therapeutic effects of these compounds through dose, delivery mechanism and personalised psychological support, Beckley Psytech aims to optimise treatment outcomes and reduce the burden on the patient, healthcare systems and society.

More about our
Clinical trials

By enhancing the psychedelic treatment paradigm with digital tools to track, report and even predict patient outcomes, Beckley Psytech aims to redefine patient journeys, in order to deliver personalised treatment programmes that improve patient outcomes, reduce healthcare resource utilisation and bring meaningful change for patients.

More about

By utilising AI-based technologies to research novel compositions of psychedelic compounds and new chemical entities, Beckley Psytech’s drug discovery engine, Beckley Deep Labs, is creating the next-generation of psychedelic-inspired medicines.

More about
Beckley Deep Labs

We are developing a pipeline of differentiated psychedelic products for psychiatric and neurological conditions:


Currently available medications are not effective for all people with depression. Treatment Resistant Depression (TRD) is the term used when two or more different antidepressant medicines have been ineffective and occurs in up to a third of people suffering with Major Depressive Disorder (MDD). TRD places a huge burden on the healthcare system. Our approach to psychological support targets clinically meaningful improvements in a less time-and resource-intensive session through the use of high potency, short-acting psychedelic medicines.

Alcohol Use Disorder

Alcohol Use Disorder (AUD) is a medical condition characterised by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, alcohol addiction, and the colloquial term, alcoholism. AUD is a common and deadly condition. According to the Centre for Disease Control (CDC), more than 140,000 people die in the US from AUD every year1.Some people with alcohol use disorder who wish to abstain from or reduce alcohol consumption do not achieve their treatment goal with currently approved treatment options2. There remains a huge unmet medical need for these patients and an opportunity for new treatment approaches.

1. Deaths from Excessive Alcohol Use in the United States2. National Institute of Alcohol Abuse and Alcoholism